Minocycline as Treatment for Psychiatric and Neurological Conditions: A Systematic Review and Meta-Analysis

Author:

Panizzutti Bruna1ORCID,Skvarc David2ORCID,Lin Sylvia13ORCID,Croce Sarah1,Meehan Alcy1,Bortolasci Chiara Cristina1,Marx Wolfgang1ORCID,Walker Adam J.1,Hasebe Kyoko4ORCID,Kavanagh Bianca E.1,Morris Margaret J.4ORCID,Mohebbi Mohammadreza15ORCID,Turner Alyna1ORCID,Gray Laura1,Berk Lesley1,Walder Ken1ORCID,Berk Michael167,Dean Olivia M.16ORCID

Affiliation:

1. IMPACT, Institute for Innovation in Physical and Mental Health and Clinical Translation, Barwon Health, School of Medicine, Deakin University, Geelong, VIC 3220, Australia

2. School of Psychology, Faculty of Health, Deakin University, Geelong, VIC 3220, Australia

3. Melbourne Neuropsychiatry Centre, University of Melbourne, Parkville, VIC 3053, Australia

4. School of Biomedical Sciences, UNSW Sydney, Kensington, NSW 2052, Australia

5. Biostatistics Unit, Faculty of Health, Deakin University, Burwood, VIC 3125, Australia

6. Florey Institute for Neuroscience and Mental Health, University of Melbourne, Parkville, VIC 3052, Australia

7. Orygen, The National Centre of Excellence in Youth Mental Health, Parkville, VIC 3052, Australia

Abstract

Minocycline has anti-inflammatory, antioxidant, and anti-apoptotic properties that explain the renewed interest in its use as an adjunctive treatment for psychiatric and neurological conditions. Following the completion of several new clinical trials using minocycline, we proposed an up-to-date systematic review and meta-analysis of the data available. The PICO (patient/population, intervention, comparison and outcomes) framework was used to search 5 databases aiming to identify randomized controlled trials that used minocycline as an adjunctive treatment for psychiatric and neurological conditions. Search results, data extraction, and risk of bias were performed by two independent authors for each publication. Quantitative meta-analysis was performed using RevMan software. Literature search and review resulted in 32 studies being included in this review: 10 in schizophrenia, 3 studies in depression, and 7 in stroke, with the benefit of minocycline being used in some of the core symptoms evaluated; 2 in bipolar disorder and 2 in substance use, without demonstrating a benefit for using minocycline; 1 in obsessive-compulsive disorder, 2 in brain and spinal injuries, 2 in amyotrophic lateral sclerosis, 1 in Alzheimer’s disease, 1 in multiple systems atrophy, and 1 in pain, with mixes results. For most of the conditions included in this review the data is still limited and difficult to interpret, warranting more well-designed and powered studies. On the other hand, the studies available for schizophrenia seem to suggest an overall benefit favoring the use of minocycline as an adjunctive treatment.

Funder

Trisno Family Fellowship

NHMRC Senior Principal Research Fellowship and Leadership 3 Investigator

NHMRC Investigator

Multiple Sclerosis Research Australia early-career fellowship

Publisher

MDPI AG

Subject

Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis

Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3